BioSpace News Archive

Menarini Silicon Biosystems (MSB), Inc. is announcing that the AMA has issued Current Procedural Terminology (CPT®) Proprietary Laboratory Analyses (PLA) codes for two of its CELLSEARCH advanced liquid biopsy tests which received preliminary pricing determination by the US Centers for Medicare and Medicaid Services (CMS). Issuing of these codes represents a decisive step towards gaining broad access to Medicare/Medicaid reimbursement.

InMode Ltd. announced that it expects to release its financial results for the third quarter of 2022 before the Nasdaq market opens on Thursday, October 27, 2022.

Insmed Incorporated today announced that it will release its third quarter 2022 financial results on Thursday, October 27, 2022.

INOVIO today announced positive interim results from an ongoing Phase 1/2 clinical trial evaluating INO-3107 for the treatment of HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) in adults.

Maze Therapeutics today announced that Harold Bernstein, M.D., Ph.D., a 30-year industry veteran, has been appointed as president, head of research and development (R&D) and chief medical officer.

QT Imaging, Inc. announced the award of a five-year National Cancer Institute grant to study the progress of neo-adjuvant therapy for women with breast cancer using the QTscan.

Dermavant to Present Data from Multiple Clinical Trials of VTAMA ® (tapinarof) cream, 1% at the 2022 Fall Clinical Dermatology Conference.

Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced that Ascendas Genomics has received approval from the National Medical Products Administration (NMPA) of China for use of the company’s Biomark™ family of systems and its Juno™ system in NMPA molecular diagnostics services.

Today, Neurophth Therapeutics, Inc. has a special interview with Dr. Satoshi Kashii, Professor of Visual Sciences and Ophthalmology, Aichi Shukutoku University, President of Asian Neuro-Ophthalmology Society, to understand his perspectives on LHON.

Epic Bio today announced a presentation on the company’s unique engineering platform, called the Gene Expression Modulation System (GEMS), at the co-hosted Solebury / BMO Fall Private Company Showcase.